Compare HROW & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | IMKTA |
|---|---|---|
| Founded | 1998 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2008 | 1994 |
| Metric | HROW | IMKTA |
|---|---|---|
| Price | $39.48 | $86.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $69.86 | N/A |
| AVG Volume (30 Days) | ★ 550.4K | 110.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,334,032,609.00 |
| Revenue This Year | $31.62 | N/A |
| Revenue Next Year | $50.77 | N/A |
| P/E Ratio | ★ N/A | $15.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.54 | $63.75 |
| 52 Week High | $54.98 | $95.62 |
| Indicator | HROW | IMKTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 45.08 |
| Support Level | $37.03 | $86.26 |
| Resistance Level | $41.82 | $91.00 |
| Average True Range (ATR) | 1.80 | 2.79 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 49.15 | 28.99 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.